Press Releases

Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing

LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and

LA JOLLA, Calif. , July 1, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7% reduction in severe

Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET / 5:30 a.m. PT LA JOLLA , Calif.  , June 26, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated

Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024 with data expected in 2025 Collaborators from Cedars-Sinai to

Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif. , May 7, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on

Full target enrollment of 216 patients achieved  Topline data from CARPO expected in 2Q 2024   LA JOLLA, Calif. , April 24, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated

Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024   Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI); KOURAGE initiating in 2Q 2024 CRSPA Phase 1/2 trial of

Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical observations made with Auxora, supporting the KOURAGE trial in patients with severe AKI that will start